KPC Pharmaceuticals Inc, a leading drug maker headquartered in Yunnan province, has accelerated its research and development endeavors to diversify its product offerings and strengthen its global presence, with a particular focus on botanical medicines.

Leveraging the province's trove of medicinal plants, KPC is sharpening its focus on treatments for chronic diseases and healthy aging. Central to this strategy is its proprietary "777" brand, focused on the Panax notoginseng series, one of more than 40 natural botanical drugs the company has developed.

"By focusing on the '777' brand, we aim to strengthen our position in chronic disease management and deliver effective solutions to patients globally," Yan Wei, KPC president, said.

"Our commitment to innovation and research remains unwavering as we continue to explore new frontiers in natural medicine."

Founded in 1951, KPC boasts a long history of pharmaceutical innovation. The company was listed on the Shanghai Stock Exchange in 2000, a milestone that marked the beginning of its expansion into international markets. Today, KPC operates more than 50 subsidiaries and sells products in over 60 countries.

The company has been recognized as a national high-tech enterprise and a leader in intellectual property, with notable achievements including the advancement of artemisinin, a groundbreaking anti-malarial treatment.

Currently, KPC is in what it calls a strategic phase of high-quality development and innovation. Beyond strengthening its Chinese medicine portfolio highlighted by the "Kunming TCM 1381" brand, which holds a Guinness World Record as the world's oldest continuously operating pharmaceutical business, the company is targeting the rapidly growing "silver age" health industry.

Its research pipeline is designed to address core areas of elderly health and chronic disease, including cardiovascular and musculoskeletal. In 2025, KPC reported progress in several innovative drug programs. Among them, a natural medicine for ischemic stroke, which is advancing in Phase II clinical trials.

KPC is also stepping up its global push with artemisinin products, particularly in Africa, where it has become a leading brand in malaria treatment. The company manages the entire value chain from seed cultivation to international distribution, bolstering its competitiveness in overseas markets.